DBS: “We are moving past the idea that one treatment fits all”
sponsored by Medtronic
Author: MedtronicPublished: 26 November 2020
Prep: Cook: Serves:
A deep brain stimulation device – launched by global medical technology company Medtronic – continuously records patients’ brain signals and creates a “diary of motor symptoms”. Two experts share how the technology is introducing a new era of personalised Parkinson’s treatments
“New technologies are very important to further increase the benefit of deep brain stimulation,” says Maria Fiorella Contarino (pictured above), a neurologist based in the Netherlands.
For two decades, Dr Contarino has worked in the field of deep brain stimulation (DBS) – a surgical procedure in which electrodes are placed in specific regions of the brain to treat movement disorders like Parkinson’s.
Using traditional DBS technology, clinicians can measure the activity of a patient’s brain cells during surgery or in clinical settings – and set a frequency and amplitude to stimulate the patient with, 24 hours a day. A new wave of technology launched earlier this year – including the Percept™ PC neurostimulator with BrainSense™ technology – aims to tailor this treatment to the needs of individual patients by continuously recording brain signals in any setting.
“What’s new now with the Percept™ PC neurostimulator is that you can get the same information from the patient at home, and not only in an experimental setting. This opens up the possibility of collecting huge amounts of data – and this is very much needed because all the patients are different,” says Dr Contarino. “There is a chance for both the neurologists and the patients to peek inside the brain, see what the signature mark of the disease is, and how deep brain simulation can change and improve it.”
Created by global medical technology company Medtronic, the Percept™ PC neurostimulator also comes with a Patient Programmer – a handheld device that allows users to control their stimulators and record any changes in brain activity. So far, Dr Contarino has implanted the new neurostimulator into two patients.
“Physicians can use it in two ways,” she explains. “One is when the patient is present in the office, enabling the physician to check what the brain signals are at that moment and adjust the simulation settings accordingly. The second way is via at-home recording, when we switch the recordings on, and the patient goes home. We can then record signals for weeks, so, when the patient returns to the office, we potentially have a sort of diary of the motor symptoms. Based on this information, we could then decide whether the stimulation parameters are good or not.”
Tailoring treatment to a single patient
“These types of technologies are new for nearly everyone,” says Gaetano Leogrande, a senior research and development engineer who helped develop the technology behind the Percept™ PC neurostimulator – BrainSense™.
Leogrande supports healthcare practitioners like Dr Contarino to understand and use the BrainSense™ technology, offering training and answering any questions.
In the future, Leogrande says, it is hoped that the stimulation will be adaptive. This means that the stimulation will be “automatically and frequently adapted according to the needs of a specific patient at a specific point in time”.
“This is important because we hope that it will reduce symptom fluctuations, reduce side effects and extend the longevity of the device, so we won’t have to bother the patient with as many replacement sessions,” he explains.
Tailoring DBS to the needs of each patient is necessary because “every patient has a different form of the disease”, says Dr Contarino. “There are some patients who have more tremors, some who are slower, some with symptoms that are more on one side of the body […] There are patients of all ages – young and old. And, even within the same patient, symptoms can change as the disease progresses.”
With the Percept™ PC neurostimulator, she says: “We are moving past the idea that one treatment fits all. Of course, traditional stimulation gives a consistent and significant improvement to all the patients1, but maybe if we can further tailor the treatment to a single patient or even to a single day of that patient’s life, we can improve it even more.”
Gaetano Leogrande is a senior research and development engineer at Medtronic.
A generational step for DBS
Discussing the response to the technology so far, Leogrande says: “Clinicians seem to be very excited about the technology, the information it provides, and the ease of use. Recently the technology was defined as a game changer by one of the main opinion leaders in this field, because it provides data that cannot be obtained in other way.”
According to Dr Contarino, it’s too early to comment on the advantage of this new system for her patients, but she does say “they’re happy that there is ongoing research and technical advances into the DBS treatment”.
Looking ahead to future developments for the Percept™ PC neurostimulator, Dr Contarino says: “The next step is to study the brain further and try to get more data – and then try to automatize the adaptive stimulation. We want to teach the system to recognise the signals and to set up the best parameters automatically. This will be a big improvement.”
Leogrande adds: “The age of the world’s population is increasing, and it means we can expect more and more people to need these therapies and solutions – so we cannot stop research in understanding how to better care for these patients. My personal belief is that in a few years from now, we’ll be able to collect enough data with this device to use artificial intelligence to predict the evolution of Parkinson’s. This might really be a generational step for the understanding of the brain and the titration of DBS.”
Medtronic’s Percept™ PC neurostimulator with BrainSense™ technology.
At a glance: benefits of the Percept™ PC neurostimulator
It can continuously sense and record brain signals, allowing clinicians to track patient-specific signals and correlate these with patient-recorded events
It’s the only DBS system that is compatible with 3T full-body MRI scans*, meaning it can be left on with certain stimulation configurations while the scans take place
It incorporates low pulse width, providing expanded stimulation options
It has improved battery longevity** and a comfortable new shape
It has an enhanced Patient Programmer*** through a custom-configured Samsung mobile device, allowing patients to manage their therapy more easily.
Need to know
Maria Fiorella Contarino is a neurologist who works at Haga Teaching Hospital and Leiden University Medical Centre, the Netherlands. Her main field of interest is movement disorders and, in particular, advanced treatments for Parkinson’s disease, such as deep brain stimulation. She has worked in the field of deep brain stimulation surgery for more than 20 years.
Gaetano Leogrande is a senior research and development engineer at the Medtronic Bakken Research Centre in the Netherlands. For eight years, he has worked in the field of deep brain stimulation and its application for Parkinson’s disease, essential tremor, dystonia and obsessive-compulsive disorders. As part of his role at Medtronic, he supports healthcare practitioners to better understand and use the Percept™ PC neurostimulator.
Brief Statement: See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScan® device, see the MRI SureScan® technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.
Disclaimer: Information contained herein does not replace the recommendations of your healthcare professional. See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your Health Care Professional.
* Medtronic DBS systems are MR Conditional, which means they are safe for MRI scans only under certain conditions. If the conditions are not met, the MRI could cause tissue heating, especially at the implanted lead(s) in the brain, which may result in serious and permanent injury or death. Refer to the MRI Guidelines for Medtronic Deep Brain Stimulation Systems for a complete list of conditions: http://professional.medtronic.com/mri
**Compared to Activa™ PC device. For median energy use in DBS for patients with Parkinson’s disease, with equivalent settings and no BrainSense™ technology usage
***Compared to the 37642 DBS Patient Programmer for use with Activa™ devices
This article is sponsored by Medtronic. The information in this article is given for information purposes only and does not represent an endorsement by the European Parkinson’s Disease Association of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
‘Chopsticks are not easy for a person with Parkinson’s’
In the third in our series on this year’s World Parkinson Congress (WPC),
6 days ago
Could a sea sponge support the search for Parkinson’s disease treatments?
How could a molecule in a sea sponge help treat Parkinson’s and similar conditions? Researchers at the University of California, Los Angeles (UCLA), in the US, recently explored this question. Their findings were published in the journal ‘Science’. The team examined a molecule known as lissodendoric acid A, which appears to counteract other molecules that damage DNA, proteins and whole cells – and was recently discovered in a sea sponge. The research team used an oft-neglected compound called a cyclic allene to control a step in the chain of chemical reactions, which enabled them to create a version of the molecule in a lab. Scientists believe that the ability to synthetically produce lissodendoric acid A will help them assess whether it can inform future therapies for conditions like Parkinson’s. UCLA’s Professor Neil Garg, the corresponding author of the study, said: “We hope others will also be able to use cyclic…
Study finds just six minutes of daily exercise might delay onset of Parkinson’s disease
Regular exercise is a common therapeutic strategy for people with Parkinson’s. Now, a study from New Zealand has suggested that daily physical activity might even delay the onset of this condition. Published in ‘The Physiological Society’, the study focused on a protein called brain-derived neurotrophic factor (BDNF) – which has previously been shown to boost cognitive performance. The researchers assessed the impact of fasting and physical activity on BDNF production in 12 people aged 18 to 56. The tests involved fasting and completing exercises of varying intensity, such as cycling for six minutes, as well as combinations of both fasting and physical activity. The results showed that brief, intense exercise was the best option for increasing the production of BDNF – with the protein increasing by a factor of four to five times compared to light exercise or fasting. Because BDNF can protect the brain from cognitive decline, the findings could…
Machine learning may help predict risk of freezing of gait in Parkinson’s disease
Difficulty taking steps forward, often referred to as the freezing of gait (FOG), is a common symptom experienced by people with Parkinson’s and one that can be difficult to predict. China-based researchers suggest that machine learning – artificial intelligence (AI) that uses algorithms to analyse data – could help predict the risk of freezing of gait developing in the early stages of the condition. Their study, published in ‘npj Parkinson’s Disease’, gave laboratory and clinical data to a machine learning model brain. This information was collected from 158 adults with untreated early-stage Parkinson’s and 73 healthy adults over a five-year period. They found that the risk of FOG could be predicted with an accuracy rate of up to 78%. The study authors suggested that machine learning methods “have the potential to help predict future FOG in patients with early Parkinson’s at an individual level”.